Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCRATES Test Kit Helps Develop First Metabolomics-Based Blood Test for Alzheimer’s

Published: Tuesday, March 18, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
The test is capable of predicting, with 90% accuracy, the risk of Alzheimer’s disease 2–3 years before it has actually become clinically manifest.

The findings, published in Nature Medicine, were generated using the validated AbsoluteIDQ® p180 test kit by Austrian BIOCRATES Life Sciences AG, a leading developer of innovative metabolomics solutions.

A team of researchers in Georgetown, Washington DC, and Rochester, New York, has developed the world’s first blood test capable of predicting Alzheimer’s disease. The first-of-its-kind study, recently published in Nature Medicine, used the AbsoluteIDQ® p180 test kit by BIOCRATES Life Sciences AG, a leading Austrian biotech company specialized in targeted metabolite quantification. 

Alzheimer’s disease currently affects more than 35 million individuals worldwide, and this figure is expected to increase to up to 150 million by 2050. A cure for Alzheimer’s disease is currently not available, but early detection could contribute to substantially improving the situation of affected individuals. While biomarkers have long been expected to provide important clues to the early causes of Alzheimer’s disease, current biomarkers are either invasive, time-consuming, or costly. The team around Mapstone and Federoff now discovered that a set of 10 lipids from peripheral blood predicts the development of mild cognitive impairment or Alzheimer’s disease with over 90% accuracy and 2–3 years in advance. Although it will take some time to develop test versions fit for use in doctors’ offices, the findings by Mapstone et al. are an impressive example of the power of metabolomics in diagnosis and biomarker discovery.

AbsoluteIDQ p180 provides extensive metabolic information from a single targeted assay, quantifying 186 analytes from 5 substance classes in a high-throughput manner. It features the advanced proprietary MetIDQ™ software solution, requires minute sample volumes (10 µL), and is suitable for use with a wide range of biological samples, making it an excellent choice for researchers looking for a cost-effective solution to measure endogenous metabolites under quality-controlled conditions. The AbsoluteIDQ kits by BIOCRATES have been successfully applied in many different areas, including diabetes, nephrology, sepsis, and CNS disorders, in both clinical and pharmaceutical research.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BIOCRATES Goes Spain and Turkey
Austrian diagnostic expert in personalized medicine continues to expand its European distribution network.
Thursday, May 10, 2012
BIOCRATES and Selexis Join Forces to Optimize High-yield Mammalian Cell Cultures
The agreement enables both the parties to combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.
Tuesday, August 31, 2010
BIOCRATES Joins European Research Consortium – SysKid
The Company has joined a multi-partner European research program dedicated to improving the diagnosis and treatment of chronic kidney disease.
Thursday, April 01, 2010
BIOCRATES’ Metabolomics Expertise Provides New Insight into Functional Genomics
German researchers used Biocrates’ metabolomics expertise in research linking the genetic make-up of an individual to differences in their metabolism.
Tuesday, February 03, 2009
BIOCRATES Participates in 2.9€ Million EU Cancer Diagnostics Project
The latest framework six EU projects called COBRED will use technology platforms to find diagnostic biomarkers for two of the most common cancers, Colon and Breast Cancer.
Friday, May 11, 2007
Biocrates Raises €5 Million in Venture Financing
This investment further strengthens Biocrates’ position in the field of high content analysis and discovery of multiparametric biomarkers.
Thursday, June 29, 2006
Scientific News
Could the Food we Eat Affect Our Genes?
Almost all of our genes may be influenced by the food we eat, according to new research.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Microbiome May Hold the Key to Fighting Obesity
In a unique study of free-ranging brown bears, Swedish researchers were able to show that the bears’ dietary variation goes hand-in-hand with dramatic changes in the animal’s gut microbiota.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Toxicity Testing With Cultured Liver Cells
Microreactor replaces animal testing.
Proteins Seek, Attack, Destroy Tumor Cells in Bloodstream
Using white blood cells to ferry potent cancer-killing proteins through the bloodstream virtually eliminates metastatic prostate cancer in mice, Cornell researchers have confirmed.
Why Do Some Infections Persist?
In preparing for the possibility of an antibiotic onslaught, some bacterial cultures adopt an all-for-one/one-for-all strategy that would make a socialist proud, University of Vermont researchers have found.
Flipping Molecular 'Switch' May Reduce Nicotine's Effects in the Brain
Scientists at The Scripps Research Institute (TSRI) have discovered that a lipid (fat molecule) in brain cells may act as a “switch” to increase or decrease the motivation to consume nicotine.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!